Cellectis S.A. CLLS Stock Forecast
AI-powered price prediction and analysis for Cellectis S.A. · Alpha · vs marketSwitch to Total
See CLLS's Exact Price Target · Create a free account and follow this stock to unlock its full AI forecast — 3 stocks free.
Price Chart
Key Statistics
About Cellectis S.A.
Cellectis S.A. (CLLS) operates within the Life Sciences sector, specifically in the Biological Products, (No Diagnostic Substances) industry.
Latest News
Where CLLS sits on the market map
Biological Products, (No Diagnostic Substances) Peers
Companies sharing the same SEC industry code, one row per issuer, largest first - a classification match, not a curated list of competitors.
| Company | AI Signal | Market Cap | P/E |
|---|---|---|---|
| CLLS Cellectis S.A. | ▶ | $118M | – |
| AMGN Amgen Inc | ▼ | $223.19B | 25.5x |
| GILD Gilead Sciences, Inc. | ▶ | $183.41B | – |
| MRNA Moderna, Inc. | ▲ | $85.33B | – |
| ARGX Argenx Se | ▶ | $49.67B | – |
| RVMD Revolution Medicines, Inc. | ▲ | $41.57B | – |
| BIIB Biogen Inc. | ▼ | $33.79B | 23.6x |
| BNTX Biontech Se | ▶ | $22.51B | – |
| MESO Mesoblast Ltd | ▼ | $18.51B | – |
| EXEL Exelixis, Inc. | ▲ | $14.75B | – |
| NBIX Neurocrine Biosciences Inc | ▼ | $14.37B | 20.4x |
| HALO Halozyme Therapeutics, Inc. | ▲ | $12.61B | 30.5x |
| TECH Bio-Techne Corp | ▼ | $11.38B | 62.6x |
| PCVX Vaxcyte, Inc. | ▲ | $10.51B | – |
| IBRX Immunitybio, Inc. | ▲ | $10.39B | – |
| KRYS Krystal Biotech, Inc. | ▲ | $9.83B | 40.7x |
| QGEN Qiagen N.V. | ▼ | $9.83B | – |
| RGEN Repligen Corp | ▲ | $9.74B | 234.4x |
| TWST Twist Bioscience Corp | ▲ | $9.52B | – |
| KYMR Kymera Therapeutics, Inc. | ▲ | $9.32B | – |
| IOVA Iovance Biotherapeutics, Inc. | ▲ | $6.60B | – |
| KOD Kodiak Sciences Inc. | ▲ | $6.24B | – |
| IMVT Immunovant, Inc. | ▲ | $6.09B | – |
| CGON Cg Oncology, Inc. | ▲ | $5.53B | – |
| SRRK Scholar Rock Holding Corp | ▲ | $5.11B | – |
| CRSP Crispr Therapeutics Ag | ▲ | $4.84B | – |
| ADPT Adaptive Biotechnologies Corp | ▲ | $4.03B | – |
| RLAY Relay Therapeutics, Inc. | ▲ | $3.94B | – |
| TARS Tarsus Pharmaceuticals, Inc. | ▲ | $3.26B | – |
| DNLI Denali Therapeutics Inc. | ▲ | $2.94B | – |
| DBVT Dbv Technologies S.A. | ▼ | $2.67B | – |
| BEAM Beam Therapeutics Inc. | ▲ | $2.52B | – |
| ADMA Adma Biologics, Inc. | ▲ | $2.31B | 13.7x |
| RXRX Recursion Pharmaceuticals, Inc. | ▲ | $2.15B | – |
| NVAX Novavax Inc | ▲ | $2.09B | – |
| VCEL Vericel Corp | ▶ | $2.08B | 85.9x |
| BCRX Biocryst Pharmaceuticals Inc | ▲ | $2.06B | – |
| VIR Vir Biotechnology, Inc. | ▲ | $1.91B | – |
| ALVO Alvotech | ▶ | $1.68B | – |
| SCNI Scinai Immunotherapeutics Ltd. | ▶ | $1.61B | – |
| MAZE Maze Therapeutics, Inc. | ▲ | $1.54B | – |
| IMCR Immunocore Holdings Plc | ▲ | $1.50B | – |
| COAG Hemab Therapeutics Holdings, Inc. | ▲ | $1.39B | – |
| TSHA Taysha Gene Therapies, Inc. | ▲ | $1.35B | – |
| REPL Replimune Group, Inc. | ▲ | $1.23B | – |
| VOR Vor Biopharma Inc. | ▶ | $1.17B | – |
| VALN Valneva Se | ▼ | $1.03B | – |
| JATT Zura Bio Ltd | ▼ | $1.01B | – |
| MGTX Meiragtx Holdings Plc | ▶ | $997M | 12.6x |
| IMTX Immatics N.V. | ▶ | $967M | – |
| CGEM Cullinan Therapeutics, Inc. | ▲ | $907M | – |
| ODTX Odyssey Therapeutics, Inc. | ▲ | $878M | – |
| GLUE Monte Rosa Therapeutics, Inc. | ▲ | $844M | – |
| DNA Ginkgo Bioworks Holdings, Inc. | ▲ | $792M | – |
| SANA Sana Biotechnology, Inc. | ▶ | $784M | – |
| SLDB Solid Biosciences Inc. | ▲ | $719M | – |
| CADL Candel Therapeutics, Inc. | ▲ | $709M | – |
| FDMT 4d Molecular Therapeutics, Inc. | ▲ | $682M | – |
| PRME Prime Medicine, Inc. | ▲ | $655M | – |
| AURA Aura Biosciences, Inc. | ▲ | $650M | – |
FAQ
Is Cellectis S.A. a good stock to buy?
Our AI analyzes Cellectis S.A. daily. Check the signal above for the latest recommendation. Always do your own research before investing.
How accurate are Cellectis S.A. predictions?
A per-ticker accuracy statistic for CLLS is published only once its sample size is known. Across our coverage, the out-of-sample test on 4537 stocks from 2025-01-06 to 2026-06-09 produced a positive net return in 73.7% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
How often are forecasts updated?
Cellectis S.A. forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on Oct. 13, 2026.
Ready to invest smarter? · Join thousands of investors using AI-powered stock predictions
Sign Up FreeLooking for a deeper analysis of Cellectis S.A.? View full institutional-grade analysis on Intratio →
AI predictions are based on historical patterns and should not be the sole basis for investment decisions. Past performance does not guarantee future results. Always do your own research.